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To expand substantially and spread malignantly, 
a cancer must induce the formation of new blood 
vessels (Bergers and Benjamin, 2003; Ferrara 
et al., 2004). In the pivotal angiogenic switch, 
the tumor acquires the ability to produce or 
increase the bioavailability of vascular endothe-
lial growth factor (VEGF-A; herein referred to 
as VEGF), which is essential for endothelial cell 
(EC) growth and survival in the tumor vascula-
ture (Bergers and Benjamin, 2003; Ferrara et al., 
2004). Novel anticancer agents such as bevaci-
zumab, a humanized mAb against VEGF, that 
block VEGF signaling and trigger EC apoptosis 
and vascular regression have been approved for 
use in several advanced malignancies (Ellis and 
Hicklin, 2008). Despite the considerable poten-
tial of targeting the neovasculature in cancer 
therapy, the clinical responses to VEGF block-
ade have often been modest, and a better under-
standing  of  the  underlying  mechanisms  is 
clearly needed.
Although VEGF blockade is known to kill 
ECs within the blood vessels of solid tumors, 
how the ECs die has been unknown. Because 
the prosurvival protein Bcl-2 is up-regulated   
in ECs after stimulation with VEGF (Gerber   
et al., 1998), we reasoned that a proapoptotic 
BH3 (Bcl-2 homology 3)-only member of that 
family (Youle and Strasser, 2008) might initiate 
the EC death provoked by falling VEGF levels 
when solid tumors shrink during cancer ther-
apy. The BH3-only protein Bim (O’Connor   
et al., 1998) is critical for the apoptosis induced 
by cytokine deprivation in several cell types 
(Bouillet et al., 1999; Youle and Strasser, 2008), 
and notably, in early development of the eye, 
Bim is critical for the programmed cell death of 
the ECs comprising the vessels of the tunica 
vasculosa lentis, a residual embryonic vasculature 
(unpublished data). We therefore hypothesized 
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For malignant growth, solid cancers must stimulate the formation of new blood vessels by 
producing vascular endothelial growth factor (VEGF-A), which is required for the survival 
of tumor-associated vessels. Novel anticancer agents that block VEGF-A signaling trigger 
endothelial cell (EC) apoptosis and vascular regression preferentially within tumors, but 
how the ECs die is not understood. In this study, we demonstrate that VEGF-A deprivation, 
provoked either by drug-induced tumor shrinkage or direct VEGF-A blockade, up-regulates 
the proapoptotic BH3 (Bcl-2 homology 3)-only Bcl-2 family member Bim in ECs. Impor-
tantly, the tumor growth inhibitory activity of a VEGF-A antagonist required Bim-induced 
apoptosis of ECs. These findings thus reveal the mechanism by which VEGF-A blockade 
induces EC apoptosis and impairs tumor growth. They also indicate that drugs mimicking 
BH3-only proteins may be exploited to kill tumor cells not only directly but also indirectly 
by ablating the tumor vasculature.
© 2011 Naik et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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microvessel density (Hasan et al., 2002) and flow cytome-
try using CD31 as a marker of ECs. As CD31 is also ex-
pressed on a small subset of leukocytes, we sought to confirm 
the identity of the CD31+ structures in our microvessel den-
sity analysis (Fig. 2, A and B). Immunolabeling for both   
F4/80 (macrophages) and von Willebrand factor (vWF; ECs)   
revealed that macrophage infiltrate was minimal and that 
vWF+ ECs coalesced to form luminal structures consistent 
with  blood  vessels  and  identical  to  that  observed  with 
that Bim might be responsible for the EC death that is in-
duced by deprivation or blockade of VEGF in tumor-associated 
blood vessels.
RESULTS AND DISCUSSION
Novel experimental system to examine the impact  
of tumor shrinkage and the resulting VEGF reduction  
on tumor vasculature
We wanted first to explore whether the tumor shrinkage that 
accompanies chemotherapy impairs the tumor vasculature. 
However, conventional anticancer drugs can complicate stud-
ies of the relationship between the tumor and its vasculature 
by directly killing the ECs (Miller et al., 2001). Thus, we de-
veloped  an  experimental  system  that  reveals  how  tumor 
shrinkage affects ECs in the absence of direct toxicity to the 
tumor vasculature. Mouse B16.F1 melanoma and 3LL–Lewis 
lung carcinoma (LLC) cells were rendered sensitive to the 
otherwise nontoxic prodrug ganciclovir (GCV) by introduc-
tion of a vector allowing expression of a hyperactive form of 
thymidine kinase (TK; Black et al., 2001). After confirmation 
of their sensitivity to GCV in vitro (Fig. S1, A–C), these cells 
were injected subcutaneously into syngeneic WT or Bim/ 
mice to establish solid tumors. In these animals, GCV treat-
ment should only directly kill the tumor cells.
We first assessed how tumor shrinkage affected VEGF levels. 
Three daily injections of GCV produced a comparable drop 
in B16.F1 tumor weight in WT and Bim/ mice (Fig. S1 D). 
Daily examinations showed that the reduction in the intra-
tumoral levels of VEGF within GCV-treated tumors coincided 
with the reduction in tumor growth and tumor volume (Fig. S1, 
E and F). This is consistent with the notion that the B16.F1 
cancer cells are major producers of VEGF within the tumors. 
Fractionation of nontumor (GFP) and tumor cell popula-
tions (GFP+) confirmed that both populations expressed ap-
preciable levels of VEGF (Fig. S1 G). However, as tumor cells 
comprise the bulk of the tumor mass, tumor cell–specific killing 
mediated by GCV should account for most of the reduction 
in intratumoral VEGF levels. VEGF120 and VEGF164 isoforms 
predominate in both mouse and human tumors (Ferrara et al., 
1991), and it was revealed that in the majority of GCV-
treated B16.F1 tumors, at least one of these VEGF isoforms 
was substantially reduced (Fig. 1 A). Indeed, ELISA readings 
confirmed that GCV treatment provoked a precipitous drop in 
intratumoral VEGF levels: 91% in WT and 85% in Bim/ 
animals (Fig. 1 B). Accordingly, immunohistochemical stain-
ing of B16.F1 tumors showed that the GCV-induced tumor 
shrinkage led to large areas devoid of VEGF (Fig. 1 C).
Bim drives the EC apoptosis evoked by the drop  
in VEGF levels
Because the tumor vasculature in these animals is host de-
rived, comparison of tumors grown in Bim-deficient and 
WT mice allowed us to determine whether the destruction 
of the tumor vasculature relies on Bim. Importantly, in the 
Bim-deficient hosts, the loss of tumor vasculature and EC apop-
tosis was markedly reduced, as assessed by both analysis of 
Figure 1.  GCV treatment reduces VEGF expression in B16.F1  
tumors. (A) Western blot analysis of the expression of the two predominant 
isoforms of tumor-associated VEGF in homogenates of TK-expressing 
B16.F1 melanomas generated from tumors grown in WT mice treated 
with three daily injections of GCV and harvested on day 4. (B) VEGF ELISA 
performed on lysates from B16.F1 tumors treated as in A. Data represent 
mean ± SEM of five independent mice per genotype and treatment condi-
tion. (C) Representative photomicrographs of B16.F1 tumors treated as in A. 
Inset shows magnification of the boundary of VEGF-expressing and  
non-expressing tumor cells. Bar, 200 µm.JEM Vol. 208, No. 7  1353
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GCV-induced tumor shrinkage caused an 50% loss in 
viable tumor-associated ECs (CD31+ propidium iodide 
[CD31+PI]) in WT mice (P = 0.01), whereas the corre-
sponding  tumors  from  Bim/  mice  exhibited  no  such   
depletion (Fig. 2 C). This effect appears to be specific for the 
proapoptotic activity of Bim, as tumors from GCV-treated 
mice lacking the BH3-only protein Bmf, which like Bim 
has been implicated in the apoptosis induced in certain cell 
types by growth factor deprivation (Labi et al., 2008), ex-
hibited numbers of viable ECs comparable with WT con-
trols (Fig. S3).
We inferred from these results that Bim was required for 
EC  apoptosis  during  tumor  regression.  Indeed,  combined 
staining for CD31 and DNA double-strand breaks (TUNEL), 
a hallmark of apoptosis, identified abundant dying ECs in 
CD31 staining (Fig. S2 A). As anticipated, there was little 
overlap between the localization of F4/80+ and vWF+ immuno-
reactivity, indicating that few macrophages were associated 
with blood vessels. Consistent with these data, the vast   
majority of F4/80+ cells (ranging between 73 and 86%   
for all tumors and treatment conditions) did not express 
CD31 (Fig. S2 B). Thus, the CD31+ structures identified by   
immunohistochemistry and the CD31+ cells detected by 
flow cytometry represent ECs. In WT mice, the GCV-treated 
tumors exhibited fewer CD31+ vessels than the controls   
(Fig. 2, A and B) and accordingly contained more large areas of 
necrosis (Fig. 2 A). In contrast, the tumors in GCV-treated 
Bim/ mice maintained significantly greater vascularity 
(Fig. 2 B); thus, their vascular architecture was preserved, 
and they had fewer necrotic areas (Fig. 2 A). Notably, the 
Figure 2.  Bim is required for the tumor shrinkage–induced apoptosis of tumor-associated ECs. (A) TK-expressing B16.F1 melanomas were grown 
subcutaneously in WT or Bim/ mice until they reached a volume of 50 mm3, whereupon the animals were treated with three daily injections of GCV 
or saline. On day 4, sections of tumors were stained for CD31 (brown). N, necrosis. (B) Quantification of microvessel density in tumor tissue sections de-
scribed in A. Data represent the mean ± SEM (n = 4 per genotype and treatment condition). (C) FACS analysis of single-cell suspensions of tumors from 
saline- or GCV-treated WT or Bim/ mice. Data represent the mean ± SEM (n = 5 per genotype and treatment condition). (D) Tumors were subjected to 
TUNEL and CD31 staining to identify apoptotic ECs (yellow). Bars: (A) 100 µm; (D) 40 µm.1354 VEGF blockade kills endothelial cells via Bim | Naik et al.
Bim-mediated EC death is essential for VEGF  
blockade–induced inhibition of tumor growth
To causally link VEGF neutralization, Bim up-regulation, 
and EC apoptosis, we treated 3LL-LLC–bearing animals with 
VEGF-blocking mAbs (Liang et al., 2006). As with GCV-
induced  tumor  shrinkage,  direct  VEGF  blockade  in  WT 
mice substantially reduced both vascularization (Fig. 4 A) and 
the number of tumor-associated ECs (Fig. 4 B). In contrast, 
neither vessel density nor ECs decreased in the tumors of 
Bim/ mice (Fig. 4, A and B). Moreover, apoptotic ECs 
(Fig. 4 D, dashed boxes) were prevalent in the carcinomas 
from WT animals treated with anti-VEGF antibody but scarce 
in those tumors from Bim/ mice. Like the GCV treatment 
of mice bearing TK-expressing tumors, VEGF blockade aug-
mented Bim expression. The proportion of tumor-associated 
ECs with elevated Bim transcription increased significantly 
after anti-VEGF antibody treatment of both the lung car-
cinoma and melanoma (Fig. 4 C and not depicted). Notably, 
3LL-LLC–bearing mice lacking the BH3-only proteins Puma 
or Bid did not exhibit any significant protection of ECs after 
anti-VEGF treatment (Fig. 4 E). Thus, Bim is the principal 
initiator of this apoptotic response in ECs.
As observed with other tumors (Liang et al., 2006), VEGF 
blockade significantly slowed the growth of the 3LL-LLC in 
WT mice (Fig. 4 F). In striking contrast, the tumors in anti-
VEGF antibody–treated Bim/ mice grew much faster, in-
deed at rates comparable with those in control IgG–treated 
Bim/ or WT animals (Fig. 4 F). To exclude the possibility 
that loss of the proapoptotic function of Bim in hematopoietic 
cells (Bouillet et al., 1999) might have impacted the response 
of tumors to VEGF blockade in Bim/ mice, we performed 
reciprocal hematopoietic reconstitutions (with reconstitution ef-
ficiency >85%; unpublished data) and evaluated the response 
GCV-treated tumors from WT animals but few in equivalent 
tumors from Bim/ animals (Fig. 2 D). In support of the re-
sults from the melanoma tumor model, experiments with the 
lung carcinoma cells confirmed that Bim is essential for the 
intratumoral EC apoptosis provoked by the drop in VEGF 
levels elicited by GCV treatment (Fig. S4).
To monitor Bim expression in tumor-associated ECs, we 
exploited Bim-lacZ (heterozygous) knockin mice, in which a 
-galactosidase transcriptional reporter replaces the Bim cod-
ing region (Bouillet et al., 2001). Flow cytometric analysis 
of cells stained for CD31 and incubated with a fluorogenic 
-galactosidase substrate revealed that cells with high Bim 
transcription increased several-fold and peaked after two daily 
injections of GCV (on harvest day 3; Fig. 3, A and B), prob-
ably because the ECs with elevated Bim were then rapidly 
eliminated. To facilitate protein analysis, CD31+ ECs were 
isolated from saline- or GCV-treated B16.F1 tumors, and their 
purity was confirmed (Fig. S5, A–C). The level of BimEL, the 
most highly expressed isoform of Bim in the majority of tis-
sues (O’Connor at al., 1998; O’Reilly et al., 2000), was 2.4-
fold  higher  in  ECs  from  GCV-treated  than  saline-treated 
tumors (Fig. 3 C and Fig. S5 F).
Bim levels are regulated in multiple ways (Ley et al., 
2005; Youle and Strasser, 2008), and pertinently, several 
proteins implicated in its regulation were altered in tumor-
associated ECs after GCV treatment. The phosphorylated 
(active) forms of Akt and Erk1/2 were reduced (Fig. S5,   
D and E), and the reduced level of the phosphorylated (in-
active) form of FOXO3a (Fig. S5 D) is consistent with the 
activation and nuclear translocation of this transcription fac-
tor, which induces Bim transcription after cytokine with-
drawal (Dijkers et al., 2000).
Figure 3.  Drug-induced tumor shrinkage causes 
up-regulation of a Bim transcriptional reporter 
and elevated Bim protein in tumor-associated 
ECs. TK-expressing B16.F1 melanomas were grown 
and treated as described in Generation of B16.F1 and 
3LL-LLC cell lines stably expressing TK-SR39 TK.  
(A) Representative histograms depict EC populations 
with high -galactosidase (-gal) activity. Solid lines 
depict -galactosidase activity in ECs from saline-
treated tumors, dashed lines depict -galactosidase 
activity in ECs from GCV-treated tumors, and closed 
regions represent a no-FDG negative control. (B) Bar 
graph depicting the percentages of tumor-associated 
ECs with high levels of -galactosidase activity. Data 
represent the mean ± SEM (n = 3–5 for both saline 
and GCV treatments). (C) Tumor-associated ECs were 
purified from >10 WT mice treated twice with saline 
or GCV and assessed for Bim expression. HSP70 
served as a loading control, and the lysate from an 
Eµ-myc lymphoma served as a positive (+) control. 
Black lines indicate that intervening lanes have been 
spliced out.JEM Vol. 208, No. 7  1355
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Figure 4.  Bim is required for the death of tumor-associated ECs and inhibition of tumor growth on VEGF neutralization. (A) WT or Bim/ mice bearing 
subcutaneous 3LL-LLCs were treated with anti-VEGF antibody or a control Ig isotype–matched antibody when the tumors reached a volume of 50 mm3. CD31 immuno-
histochemistry revealed tumor vascularization at day 6 of treatment. (B) FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM 
(n = 5–7 for each treatment and genotype). (C) Bar graph depicts the percentages of tumor-associated ECs with high levels of -galactosidase (-gal) activity. Mice were 
treated with two daily injections of control IgG or anti-VEGF antibody and analyzed 1 d after cessation of treatment. Data represent the mean ± SEM (n = 3–5 for both 
control Ig and anti-VEGF treatments). (D) Day 6 tumors from saline- or anti-VEGF antibody–treated WT or Bim/ mice were subjected to TUNEL and CD31 staining. 
Inset shows magnification of a boxed region showing an apoptotic EC (yellow). Boxes highlight regions containing apoptotic ECs. Bars: (A) 200 µm; (D) 40 µm.  
(E) WT, Bim/, Bid/, and Puma/ mice bearing 3LL-LLC were treated with anti-VEGF neutralizing antibody as described in Mice, expression constructs, and tumor 
models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 3–5 for each treatment and genotype of mice). The data for 
WT and Bim/ mice are the same as those shown in B and are reproduced in this panel to facilitate comparison. n.s., not significant. (F) The growth of 3LL-LLC in WT or 
Bim/ mice treated with VEGF neutralizing antibody or a control Ig antibody. Mice were sacrificed when tumors exceeded a diameter of 1 cm on any orthogonal  
parameter. Data represent mean tumor volume and SEs (n = 5–17 per time point and genotype of mice; *, P = 0.047 control Ig–treated Bim/ mice vs. control Ig–treated 
WT mice; **, P = 0.0002 anti-VEGF antibody–treated WT mice vs. control Ig–treated WT mice; ***, P = 0.0001 anti-VEGF–treated Bim/ mice vs. anti-VEGF antibody–
treated WT mice). All statistical comparisons were made at day 8 of treatment. Arrows designate the days of treatment. (G) WT CD45.1+ (closed bars) or Bim/ CD45.2+ 
(open bars) recipient mice were reconstituted with unfractionated bone marrow from Bim/ CD45.2+ or WT CD45.1+ donors, respectively. The hematopoietic compart-
ment was reconstituted for 8 wk before inoculation of 3LL-LLC cells, and mice were subjected to treatment as described in Mice, expression constructs, and tumor  
models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 4–13 for each treatment and genotype of mice).1356 VEGF blockade kills endothelial cells via Bim | Naik et al.
may in part also be mediated by their ability to trigger EC 
apoptosis. These considerations suggest that a multipronged 
attack on solid tumors and their vasculature might best be 
achieved by combining a VEGF blocker with a drug that in-
hibits an oncoprotein that maintains the tumor growth (e.g., 
an epithelial growth factor receptor tyrosine kinase inhibitor 
for lung cancers with EGF-R gene mutations) and a BH3 
mimetic, which may promote apoptosis in both the tumor 
and ECs (Fig. S6 B; Cragg et al., 2009).
MATERIALS AND METHODS
Mice, expression constructs, and tumor models. All animal experi-
ments followed the guidelines of the Walter and Eliza Hall Institute of Medi-
cal Research Animals Ethics Committee. The generation of Bim/ mice 
(Bouillet et al., 1999), now backcrossed for >20 generations onto a C57BL/6 
genetic background, and Bmf/ (Labi et al., 2008), Puma/ (Villunger et al., 
2003), and Bid/ (Kaufmann et al., 2007) mice, all generated on an in-
bred C57BL/6 background using C57BL/6-derived embryonic stem cells, 
has been described previously. MMTV-PyMT transgenic mice (Guy et al., 
1992)  were  intercrossed  with  Bim/  mice  to  generate  MMTV-PyMT 
transgenic Bim/ mice, which were compared with WT (Bim+/+) MMTV-
PyMT transgenic controls. Parental B16.F1 melanoma and 3LL-LLC cell 
lines maintained in DME plus 10% FCS (Bovigen) or MT-RPMI plus 10 mM 
Hepes and 10% FCS, respectively, were provided by M. Smyth (Peter 
MacCallum Cancer Centre, Melbourne, Victoria, Australia). Clonal deriva-
tives were made expressing the mutant, hyperactive form of TK (herein re-
ferred to as TK-SR39 [Kokoris and Black, 2002]; see next section), and 5 × 105 
TK-SR39–expressing B16.F1 or 3LL-LLC cells were injected subcuta-
neously into the flanks of syngeneic C57BL/6 recipients. When tumors 
reached a volume of 50 mm3, treatment with GCV or anti-VEGF anti-
bodies was initiated. Daily intraperitoneal injections of 50 mg/kg GCV were 
administered to B16.F1 or 3LL-LLC–bearing animals for a period not ex-
ceeding 7 d. For treatment efficacy experiments, 5 mg/kg anti-VEGF mAb 
G6-31 (Genentech) was administered to 3LL-LLC–bearing animals three 
times per week for a period not exceeding 21 d. To determine tumor vol-
ume, we measured three mutually orthogonal parameters with microcalipers 
and used the formula V = w × l × d × 0.52. Mice had to be euthanized when 
tumors reached a diameter of 10 mm.
Generation  of  B16.F1  and  3LL-LLC  cell  lines  stably  expressing   
TK-SR39 TK. 10 µg plasmid DNA was linearized with ScaI, precipitated, 
and electroporated into 2.5 × 106 cells using the 240 V/960 mFD capacitance 
setting on a Gene Pulser (Bio-Rad Laboratories). Colonies were established 
by limiting dilution and screened on the basis of GFP expression to establish 
clonal cell lines. For the in vitro GCV sensitivity assay, 105 cells were plated 
into 6-well tissue culture plates 24 h before the addition of GCV. Cell viabil-
ity was determined by PI staining and FACS analysis.
Hematopoietic reconstitution. Ablation of the hematopoietic compartment 
was achieved by exposing mice to two doses of 5.5 Gy of  irradiation (from a 
60Co source) given 2 h apart. Mice were then reconstituted by intravenous 
injection of a minimum of 2 × 106 viable, total bone marrow cells in a 200-µl 
volume of PBS. Total bone marrow was harvested from two femora into 5 ml 
KDS/BSS/10% FCS, counted using trypan blue exclusion, and resuspended 
at a concentration of 1 × 107 cells/ml in PBS. Mice were maintained on 2 mg/ml 
neomycin-supplemented water for a minimum period of 21 d.
Immunohistochemistry, TUNEL staining, and image analysis. Tissues 
were harvested and fixed for 24–48 h in 10% formalin (for VEGF detection) 
or formalin-free zinc fixative (for CD31 detection and TUNEL staining; BD). 
5-µm sections were deparaffinized according to standard histological proto-
cols. For CD31 staining, epitope retrieval was achieved by incubating 
tissue specimens with 20 µg/ml proteinase K for 10 min at 37°C. For VEGF 
of tumors grown in these chimeric mice to anti-VEGF anti-
body  treatment.  The  numbers  of  viable  tumor-associated 
ECs were reduced if the ECs were WT, as in the WT mice 
reconstituted with Bim/ bone marrow, but not if the ECs 
lacked Bim, as in Bim/ mice reconstituted with a WT   
hematopoietic system (Fig. 4 G). This indicates that the pres-
ence of a Bim/ hematopoietic compartment does not affect 
the response of tumor-associated ECs to VEGF blockade.
We also observed that Bim mediates the killing of intra-
tumoral ECs after anti-VEGF antibody treatment in the mouse 
mammary tumor virus–polyomavirus transgene (MMTV-
PyMT) transgenic model of de novo mammary carcinogenesis. 
Injection of VEGF-neutralizing antibodies caused a signifi-
cant reduction in the numbers of viable tumor-associated ECs 
in MMTV-PyMT transgenic WT mice (Fig. S6 A), which 
did not occur in the corresponding MMTV-PyMT transgenic 
Bim/ animals. Collectively, these results show that Bim-
mediated apoptosis of ECs is critical for the inhibition of tumor 
growth elicited by VEGF blockade.
Key role of Bim in constraining tumor vasculature
We have clarified in this study two issues regarding the rela-
tionship between the tumor and its vasculature. The first is 
whether the tumor shrinkage that accompanies cancer ther-
apy destroys its vasculature. To avoid direct cytotoxic effects 
on ECs, we used a GCV-induced model of tumor regression 
and demonstrated that tumor shrinkage provoked a drop in 
intratumoral VEGF levels with consequent death of tumor-
associated ECs and vascular destruction. Significantly, we es-
tablished that the VEGF deprivation up-regulated the BH3-only 
protein Bim in the ECs and that Bim was responsible for 
their apoptosis in transplants of both a lung carcinoma and a 
melanoma, as well as in a de novo mammary carcinoma model. 
Consequently, it seems likely that many anticancer agents 
provoke damage to the tumor vasculature by up-regulating 
Bim in ECs.
The second issue is whether the tumor growth–inhibitory 
effects of agents that directly block VEGF signaling rely upon 
Bim-induced killing of intratumoral ECs. Indeed, Bim’s killing 
activity within tumor-associated ECs proved to be essential 
for the tumor growth inhibitory activity of VEGF blockade. 
Diverse treatment modalities provoke EC apoptosis in solid 
tumors (Dhanabal et al., 1999; Park et al., 2005); thus, poly-
morphisms in genes that control EC apoptosis, such as BIM 
or its regulators, may affect the therapeutic responses of can-
cer patients.
Our results make it likely that new antiangiogenesis agents 
could be identified that act not by modulating VEGF–VEGF-R 
signaling directly, but instead by functioning downstream 
to increase the activity of Bim or, alternatively, that mimic its 
proapoptotic action by engaging multiple Bcl-2–like pro-
survival molecules. Pertinently, small molecule mimetics of 
BH3-only proteins, such as ABT-737, have shown efficacy in 
preclinical solid tumor models (Oltersdorf et al., 2005; Cragg 
et al., 2007, 2008). Our findings indicate that their activity 
may be caused by not only direct killing of tumor cells but JEM Vol. 208, No. 7  1357
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or rabbit IgG (Millipore) and visualized using the ECL Western blot detection 
kit (GE Healthcare).
Dil-Ac-LDL (Dil acetylated low-density lipoprotein) uptake. After 
magnetic bead–assisted purification, tumor-associated ECs were resuspended 
in 1 ml serum-free DME supplemented with 10 µg/ml Ac-LDL (Biomedical 
Technologies) and incubated at 37°C for 4 h. Samples were then washed once 
and resuspended in 100 µl PBS. Cytospins were mounted in aqueous medium 
containing DAPI and visualized using a confocal microscope (CTR MIC).
Immunohistochemistry, vWF, and F4/80 staining. Tissues were har-
vested and fixed for 24 h in 4% buffered formaldehyde. 5-µm sections were 
deparaffinized according to standard histological protocols. For vWF stain-
ing, epitope retrieval was achieved by incubating tissue specimens with 
20 µg/ml proteinase K for 15 min at room temperature. This was followed 
by incubation in 0.2 M glycine (30 min) to block aldehydes and then by 
treatment for 30 min with 10% hydrogen peroxide in methanol to block 
endogenous peroxidase. Sections were then washed in PBS and incubated 
for 2 h with primary rabbit anti-vWF antibody (Dako) in PBS/1% BSA 
containing 5% normal goat serum (NGS; Vector Laboratories). This staining 
identifies ECs, megakaryocytes, and platelets. Detection was performed by 
incubating with biotinylated goat anti–rabbit Ig antibodies (Vector Laboratories) 
in PBS/1% BSA/5% NGS for 1 h at room temperature followed by detection 
with diaminobenzidine as a substrate (ABC detection kit). Sections were re-
blocked with PBS/1% BSA/5% NGS and incubated with rat anti–mouse 
F4/80 antibody or isotype-matched control antibody overnight at 4°C. De-
tection was performed with alkaline phosphatase–conjugated goat anti–rat 
IgG antibodies (Jackson ImmunoResearch Laboratories, Inc.) and blue alka-
line  phosphatase  substrate  (kit  III;  Vector  Laboratories).  Sections  were 
counterstained with hematoxylin and mounted with Aqua Poly Mount (Poly-
sciences Inc). All photographs were imaged as for TUNEL and CD31 stain-
ing, using a 20× NA 0.5 objective lens
Flow cytometric analysis of ECs and macrophages. Tumor-derived 
single-cell suspensions were prepared as described in Flow cytometric analy-
sis and FACS-Gal assay, but with the addition of a collagenase/hyaluronidase 
digestion step. Cell suspensions were stained with APC-coupled anti-CD31 
mAbs (MEC 13.3; BD) or, as a control, with an Ig isotype–matched (IgG2a/) 
rat mAb coupled to APC (R35-95; BD) plus R-PE–conjugated macrophage 
surface marker–specific mAbs anti–Mac-1 (M1/70) or F4/80 in 2% normal 
rat serum plus 2.4G2 (5 µg/ml anti-FcR mAb) to block Fc receptors. Cells 
were washed and resuspended in 10% FCS/PBS plus 1 µg/ml of the vital dye 
PI and analyzed on an LSR II (BD).
Flow cytometric sorting of tumor cells. Tumor single-cell suspensions 
were prepared as described in Flow cytometric analysis and FACS-Gal assay 
and sorted on a cytometer (MoFlo; Beckman Coulter) on the basis of GPF 
expression: PIGFP+ (viable tumor cells) and PIGFP (viable nontumor, 
i.e., stromal cells). Sorted cells were washed, resuspended at 106 cells/20 ml   
in PBS, snap frozen at 80°C, and subjected to two freeze–thaw cycles, and 
debris was removed. Total protein levels were determined using the Bradford 
assay (Bio-Rad Laboratories), and equal total protein input was used to mea-
sure  VEGF levels by ELISA.  VEGF levels (picograms) were normalized to the 
secretion from 106 cells.
Statistical analysis. For statistical comparison, two-tailed Student’s t tests 
were performed using Prism version 5.0a analysis software (GraphPad Soft-
ware), with p-values <0.05 considered significant.
Online supplemental material. Fig. S1 shows that B16.F1 and 3LL-LLC 
tumor cell lines stably expressing mutant, hyperactive TK (TK-SR39) are 
killed by GCV treatment in vitro. Fig. S2 confirms that CD31+ luminal 
structures are not macrophages. Fig. S3 shows that absence of the BH3-only 
protein Bmf does not affect the survival of tumor-associated ECs after GCV 
treatment of B16.F1 melanoma–bearing mice. Fig. S4 shows that GCV-treated 
staining, this was achieved by boiling in citrate buffer (10 mM Na citrate and 
0.05% Tween 20, pH 6.0) for 20 min. Antibodies to CD31 (MEC 13.3 at 
1/50; BD) or VEGF (Ab-4 at 1/50; EMD) were added for 1 h at room tem-
perature, and detection was performed using biotinylated polyclonal goat 
anti–rat IgG antibody (BD) or biotinylated goat anti–rabbit IgG antibody 
(Jackson ImmunoResearch Laboratories, Inc.) and the ABC detection kit 
(Vector Laboratories) with diaminobenzidine as the substrate. All photo-
micrographs were acquired using a 5× NA 0.15 or 10× NA 0.3 objective lens 
attached to a microscope (Axioplan 2; Carl Zeiss). Sequential labeling of 
CD31+TUNEL+ cells used the aforementioned protocol with streptavidin-
FITC as the secondary detection agent. Sections were then fixed with 4% 
paraformaldehyde and permeabilized with 0.2% Triton X-100 followed by 
TUNEL staining according to the manufacturer’s instructions (Apoptag Red; 
Millipore). All fluorescence images were acquired using a confocal micro-
scope (CTR MIC; Leica). Microvessel density was calculated by manual 
counting of a minimum of 10 random independent fields of view using a 40× 
objective. The criteria used to identify a microvessel included strong brown 
(CD31) staining, the presence of a lumen, and more than one CD31+ cell.
Flow cytometric analysis and FACS-Gal assay. Tumors were passed 
sequentially through a fine mesh metal sieve and 23- and 27-G needles to 
attain  single-cell  suspensions  that  were  treated  with  red  cell  lysis  buffer   
(5 min at 4°C) followed by 100 µg/ml DNase I (in BSS and incubated for   
5 min at 37°C; Roche). An aliquot of the cells was then incubated with   
50 µl primary antibody for 30 min at 4°C: 10 µg/ml anti-CD31-APC (MEC 
13.3; BD) or, as a control, with rat IgG2a coupled to APC (R35-95; BD) 
in 2% normal rat serum plus 2.4G2 (5 µg/ml anti-FcR mAb) to block Fc 
receptors. From 2 to 4 × 107 anti-CD31 antibody–stained cells (in 50 µl) 
were subjected to FACS-Gal analysis by hypotonic loading with 50 µl 
FDG (fluorescein di--galactopyranoside; Sigma-Aldrich) followed by FACS 
analysis (Elefanty et al., 1998).
Purification of tumor-associated ECs. Tumor-associated ECs were   
isolated from homogenized tumor samples using positive magnetic bead   
selection. In brief, 2 µg anti-CD31 mAb was added per 0.25 g of tumor 
(suspended in 2 ml 10% FCS/DME) and incubated at 4°C for 30 min, 
washed once, and then incubated with 2 × 107 sheep anti–rat IgG antibody–
coated magnetic beads (Dynalbeads; Invitrogen). Bead-bound cells were 
isolated using a magnetic column and washed three times with DME/10% 
FCS and once with serum-free DME. For subsequent experiments, cells 
were released from the beads by incubation with 0.05% trypsin/0.53 mM 
EDTA for 5 min at 37°C.
ELISA to measure VEGF concentration. Tumors snap frozen at 80°C 
were thawed and passed through a fine mesh sieve before suspension in 5 ml 
PBS. Samples were subjected to two freeze–thaw cycles, and debris was re-
moved by centrifugation at 13,000 rpm for 5 min. Total protein levels were 
determined using the Bradford Assay (Bio-Rad Laboratories), and samples 
were normalized to 25, 50, and 100 µg of total input protein by the addition 
of assay diluent. VEGF levels were determined using a commercially avail-
able ELISA kit (Quantikine Mouse  VEGF ELISA kit; R&D Systems) accord-
ing to the manufacturer’s instructions. VEGF concentration was calculated 
using a standard curve generated by a four-parameter logistic curve fit.
Biochemical analyses. Tumor cell suspensions were washed twice with ice-
cold PBS before lysis in ONYX lysis buffer (20 mM Tris-HCl, pH 7.4, 135 mM 
NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 2 mM Na 
orthovanadate, 50 mM Na fluoride, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and   
1 µg/ml leupeptin). 25–40 µg of total protein per sample was size-fractionated by 
gel electrophoresis (Tris-glycine Novex Pre-cast gels; Invitrogen) and transferred 
to nitrocellulose membranes (Hybond-C extra; GE Healthcare). Membranes 
were probed with antibodies to VEGF (Ab-4; EMD); Bim (Stressgen or Alexis); 
HSP70 (gift from R. Anderson [Peter MacCallum Cancer Centre]); phospho-
Erk1/2, phospho-Akt, and total Akt (all from Cell Signaling Technology); and 
phospho-FOXO3a (Thr 32 specific; Millipore), followed by the relevant horse-
radish peroxidase–conjugated secondary antibody specific to mouse, rat,   1358 VEGF blockade kills endothelial cells via Bim | Naik et al.
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3LL-LLCs grown in Bim/ mice contain more viable tumor-associated ECs 
than GCV-treated tumors grown in WT mice. Fig. S5 provides confirma-
tion of the purity of EC isolates from B16.F1 tumors and shows that the 
PI3-K–Akt and MAPK–Erk1/2 signaling pathways are modulated in tumor-
associated  ECs  after  GCV  treatment–induced  tumor  shrinkage.  Fig.  S6 
shows that Bim deficiency protects tumor-associated ECs from anti-VEGF 
treatment in a de novo transgenic mouse model of mammary carcinogenesis 
and provides a model for the multipronged approach to the treatment of 
solid tumors. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20100951/DC1.
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